ALDX Investor Alert: Aldeyra Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Disregarded FDA Requirements: Levi &...
Aldeyra Therapeutics, Inc. (ALDX)
Last aldeyra therapeutics, inc. earnings: 11/7 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.aldeyra.com/investor-relations
Company Research
Source: GlobeNewswire
NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- IMPORTANT DATE: May 29, 2026. Investors who purchased Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) securities between November 3, 2023 and March 16, 2026 and wish to seek appointment as lead plaintiff must file a motion by this date. Start your claim now before the deadline or contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500. ALDX shares collapsed $2.99 per share, a 70.7% single-day decline, closing at $1.24 on March 17, 2026 after an FDA Complete Response Letter exposed alleged failures in clinical trial evidence for reproxalap, the Company's lead dry eye disease candidate. What is a Lead Plaintiff? Under the Private Securities Litigation Reform Act of 1995, any investor who purchased ALDX securities during the class period and suffered losses may apply to serve as lead plaintiff. The court appoints the applicant with the largest financial interest who is otherwise adequate to represent the class. You do not need
Show less
Read more
Impact Snapshot
Event Time:
ALDX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALDX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALDX alerts
High impacting Aldeyra Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ALDX
News
- Pomerantz LLP Informs Shareholders of Securities Class Action Against Aldeyra Therapeutics, Inc. – ALDXACCESS Newswire
- ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ALDXGlobeNewswire
- Portnoy Law Firm Announces Class Action on Behalf of Aldeyra Therapeutics, Inc. InvestorsGlobeNewswire
- Pomerantz LLP Issues Reminder to Shareholders in Aldeyra Therapeutics, Inc. of Class Action Lawsuit – ALDXACCESS Newswire
- ALDX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aldeyra Therapeutics, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit!ACCESS Newswire
ALDX
Earnings
- 11/5/25 - Beat
ALDX
Sec Filings
- 4/27/26 - Form ARS
- 4/27/26 - Form DEFA14A
- 4/27/26 - Form DEF
- ALDX's page on the SEC website